Marshall, L.A. et al. added a selective small molecule CCR4 antagonist (CCR4-351) to a mouse model of BC in vivo and in vitro, which blocked CCL17 and CCL22, ultimately leading to Treg suppression [221]. Here, CCR4 is linked to breast cancer.